CardioCircle retweeted
Important conversations on the role of:
1) @FDA EFS & FIH trials
2) #MedTech in improving access to innovations
💡Innovation 👉Implementation
“It takes an average of 17 years for medtech solutions to reach practice” #PeterFitzgerald
💡CV care will exceed 1Trillion 💵 by 2030
💡GBD: Efficacy of vaccines 80-90% & current management of hypertension reaches only 25%
⚡ Day One starts with the science you’ll be talking about.
Dive into Featured Clinical Research at #TCT2026 WorldLink Forum for new data, hot topics, and a special session in partnership with Structural Heart ow.ly/eE6S5102GO8
#CardioX #CardioTwitter #CardioEd #CardioResearch @BurkhoffMd @djc795 @ColletCarlos @georgedangas @jgranadacrf @mbmcentegart @Drroxmehran @sahilparikhmd @PopmaJeffrey @triciarawh @mirvatalasnag @TCTConference @TCTMD @m1chaella_alex @CathWhisperer @caldera_99 @SinaDaneshMD @CAESmedmd @Julio_Farjat @GolzarianH @JyotiJain_MD @Shikha_Cardio @DrBilal_khan @KrutarthKPandya @Shoaib9702 @IoannisSkalidis @Sticchi_Alex @ricosuruagy @ladyheart_md @AnaClaraVi75147 @anast_apost @padideh_daneii @MAnisHaider @Rushil_Vasudev
CardioCircle retweeted
Free tools built by clinicians for learning the many facets of cardiology🫀🩻⚡️🧮📚🕹️
Explore these resources👇🏼:
🩻Echocardiography: intro2echo.com by @David_Ouyang
🩻Angiography Views: angioview.com by @AnnasRahmanMD
⚡️Localize PVCs: learnpvcs.com by @Challa1218
⚡️Localize VTs: simvt.vercel.app by @ArunUMahtani
⚡️LBBAP Simulator: pacingsimulator.com by @jo3_assad
🩻LAA TEE/ICE/CT Simulator: laa.liorjankelson.com by @ExtraStim
🧮Interactive Core Cardiology Tools and Calculators: tools.rueyhu.com by @ruey_hu
📚Latest Trials and Guidelines: cardiolads.com by Jay Gohri, Adhish Beri, and @KochharGunjan
🩻Interactive M Mode: pulmonarypocus.com by @HoosierPocus
🕹️Night Float Simulator: cardsnightfloat.netlify.app by @AbedfromBeirut
🕹️Congenital Heart Disease, Pacemaker, ECG Simulators: cardiorender.com by Dinesh Raja P
This list keeps growing. Know a free, clinician-built tool that belongs here? Drop the link below
#Cardiology #CardioTwitter #MedEd #MedTwitter #FOAMed #VibeCoding #AI #AIinMedicine #LLMs #DigitalHealth
@ACCinTouch @escardio @ASE360 @Heart_SCCT @HRSonline @SCAI @CardioNerds
CardioCircle retweeted
Particularly proud of the representation of women in @TCT_ME_ .. no tokenism
These are women who are leading their field from all over the world 🇸🇦 🇶🇦 🇮🇩 🇦🇪
#HaifaAlotaibi Deputy Director of RII - MODHS
@1sinusrhythm - EP
@BatoolAbuhalim1 - PERT Program
As #TCTMiddleEast2026 comes to a close, the Closing Ceremony brought together moments of reflection, appreciation and celebration following an inspiring conference.
Thank you to everyone who joined us and made #TCTMiddleEast2026 a memorable experience.
Website: tctplusme.com
Cardiovascular Research Foundation
Transcatheter Cardiovascular Therapeutics (TCT)
#cardiology #interventionalcardiology
We did it👏
As #TCTMiddleEast2026 comes to a close, the Closing Ceremony brought together moments of reflection, appreciation and celebration following an inspiring conference.
Thank you to everyone who joined us and made #TCTMiddleEast2026 a memorable experience.
Website: tctplusme.com
Cardiovascular Research Foundation
Transcatheter Cardiovascular Therapeutics (TCT)
#cardiology #interventionalcardiology
CardioCircle retweeted
انطلاق اليوم الأول من مؤتمر جمعية قسطرة القلب السعودية 🇸🇦
تنظيم متميز
نقاشات علمية ثرية
استعراض لحالات قسطرة متقدمة تحمل الكثير من الخبرة والفائدة.
ندعو المختصين والمهتمين إلى مشاركتنا الحضور والاستفادة.
الرياض- فندق موفنبيك ٤ وَ ٥ سبتمبر ٢٠٢٦
@CathGuy
@assiri99
@SACIS_KSA #SACIS2026
#PCI #InterventionalCardiology
@CathGuy @assiri99 @Jazzminem2008 @Almohammadi_M @bandar2011_
@alotaibi @Falmutairi2018 @KhalidFAlhabib
@ALNEMERK @chadialraies @YassineMedicine @Zill_cardio @ibalsaadi @alasmary31 @Nasser_Ghattar @Hragy @Dralkutshan @Dr_ShazaAlalawi @O_Azizy_MD @Sultanotb @alialmasood
@Dr_aldiri1 @DrAlsubei
CardioCircle retweeted
AFib ablation versus M-TEER in patients with functional MR!! Interesting.
Clinical Outcomes of Catheter Ablation versus Transcatheter Edge-to-Edge Repair as the Initial Intervention Strategy in Patients with Atrial Fibrillation and Functional Mitral Regurgitation #OpenAccess
@Hassan_Shirbiny
heartrhythmjournal.com/artic…
CardioCircle retweeted
🫀 ESC Heart Failure Guidelines 2026: Cardiac Imaging — Beyond LVEF: a major shift in cardiac imaging
👉 Don’t just measure EF — identify the phenotype & cause of HF.
Here are the 🔑 imaging takeaways:
🔹 Echo remains first-line
TTE remains the cornerstone of HF assessment, providing information on:
• LVEF & LV remodelling
• RV function
• diastolic function/filling pressures
• valvular disease
• pulmonary pressures
• haemodynamic consequences of HF
The message is clear: a HF echo should be much more than an EF measurement.
🔹 CMR: define the myocardial substrate
CMR is particularly valuable when echo is inadequate or the aetiology of HF/cardiomyopathy remains uncertain.
LGE and parametric mapping can identify:
➡️ scar/fibrosis
➡️ inflammation
➡️ infiltration
➡️ iron overload
➡️ characteristic cardiomyopathy patterns
This is particularly relevant in suspected myocarditis, amyloidosis, sarcoidosis & other cardiomyopathies.
🔹 CT/CTCA: answer the coronary/anatomical question
CT coronary angiography can help define or exclude CAD in appropriately selected patients.
When ischaemia rather than coronary anatomy is the question, stress echo, stress CMR, SPECT or PET may be appropriate.
🔹 Amyloidosis: imaging can establish the diagnosis
For suspected ATTR cardiac amyloidosis, evaluation integrates:
☢️ bone-tracer scintigraphy
🧪 serum/urine immunofixation + free light chains
🧲 CMR when appropriate
Identifying ATTR-CM is increasingly important given the expanding availability of disease-modifying therapies.
🔹 Cardiac sarcoidosis
FDG-PET should be considered when cardiac sarcoidosis is suspected.
CMR and PET provide complementary information:
🧲 CMR → myocardial injury/scar
☢️ FDG-PET → active inflammation
🔹 HFpEF does not mean normal function
Imaging should look beyond LVEF & assess:
➡️ diastolic dysfunction
➡️ LA remodelling
➡️ LV hypertrophy
➡️ filling pressures
➡️ pulmonary pressures
➡️ RV function
When resting investigations are inconclusive, exercise testing &/or invasive haemodynamic assessment may be needed.
🔹 Imaging before CRT/ICD
LV function should be reassessed after appropriate foundational therapy when the result will determine device eligibility.
For CRT, imaging must be integrated with the electrical phenotype.
⚡ CRT remains Class I, LoE A in appropriately selected symptomatic HFrEF patients with:
• LVEF ≤35%
• sinus rhythm
• LBBB
• QRS ≥150 ms
• despite optimal foundational therapy
🔹 2ndry MR →imaging guides intervention
Echo defines MR severity, mechanism, LV/RV function & suitability for intervention.
In appropriately selected symptomatic HFrEF + severe 2ndry MR despite optimized therapy ± CRT, mitral TEER now carries a Class I recommendation to ⬇️HF hospitalization & improve QoL.
🔹 Advanced HF: haemodynamics matter
In patients being evaluated for transplantation or durable mechanical circulatory support:
➡️ Right-heart cath— Class I, LoE C
This provides critical information on filling pressures, cardiac output and pulmonary vascular haemodynamics.
📌 The 2026 take-home message
Cardiac imaging in HF is moving from EF → phenotype &→ haemodynamics→ tissue characterization→ aetiology →targeted treatment
💡 Echo tells us how the heart is functioning.
CMR tells us about the myocardium.
CT defines anatomy.
Nuclear imaging identifies specific disease processes.
Haemodynamics completes the picture when non-invasive imaging is insufficient.
The key question is no longer simply:
“What is the EF?”
It is:
👉 “Why does this patient have HF— and will additional imaging change management?”
CardioCircle retweeted
Trajectory is the part of BASILICA I spend the most time on.
Look at the picture attached.
Electrified wire will go anywhere you point it, so you want to be sure you’re poking through a safe spot before anything gets hot.
We want to be as basal as we can on the left leaflet. Just not so basal that we end up in the aortomitral curtain.
If the AL guide won’t stand up enough to get that angle, go bigger. AL 3, 4, 5, depending on how big the aorta is. If it’s still leaning toward the mitral valve, a Supercross microcatheter will bias you off it and into the LVOT.
Then before you advance the microcatheter and lacerate, look at the TEE. You want the wire sitting free in the LVOT, not running through the anterior mitral leaflet. In BASILICA the snare helps you sort that out. In UNICORN you don’t have the snare, so the echo is it.
See you at the electrosurgical workshop @TCT_ME_ Sep 17th.
@6ayyeboon @AlkashkariWail @mirvatalasnag @BinAbdulHak_A @amrmohsen213 @MarwanSaadMD @aelsab @MusaSharkawi @djc795 @MohammedQintar @mhammadah @kalazizimd @AdamGreenbaumMD @AlhijjiM @EmoryUniversity @JDDCFratti @acamajmd @crfheart @djc795 @mmamas1973 @crfheart @BakhshiHooman @Almanfi_Cardio @Dr_ibrahimHarbi @scottiejj12
Did this case last week.
Borderline BASILICA candidate. We did it anyway.
Might argue she probably didn’t need leaflet modification for THIS valve. But if she’s back in the future for TAV in TAV, the less leaflet tissue sitting in front of the coronary, the better. This part of the life time managment of these patients, and our threshold to modify leaflets keeps getting lower.
On another point, still believe BASILICA is the better choice for native leaflets, and some data suggest it’s safer than UNICORN. The exception is severe sinus effacement. If the leaflet has no room to splay, UNICORN may be the better option.
How comfortable are we, as a field, with leaflet modification? Worth asking. The TAV in TAV in TAV patients are coming.
Will be having an electrosurgery workshop @TCT_ME_ in Riyadh next month covering the leaflet modification techniques.
@6ayyeboon @AlkashkariWail @mirvatalasnag @BinAbdulHak_A @amrmohsen213 @MarwanSaadMD @aelsab @MusaSharkawi @djc795 @MohammedQintar @mhammadah @kalazizimd @AdamGreenbaumMD @AlhijjiM @EmoryUniversity @JDDCFratti @acamajmd @crfheart @djc795 @mmamas1973 @crfheart @BakhshiHooman @Almanfi_Cardio @Dr_ibrahimHarbi @scottiejj12
CardioCircle retweeted
🫀 ESC HEART FAILURE GUIDELINES 2026 — WHAT HAS CHANGED?
The new ESC HF Guidelines bring major changes in classification, treatment, decompensation, devices and precision phenotyping.
🔹 1 | New HF classification
➡️ HFrEF: LVEF <50%
➡️ HFpEF: LVEF ≥50%
The previous HFmrEF category is removed.
🔹 2 | “Acute HF” → “Decompensated HF (DHF)”
Management focuses on identifying the trigger and rapidly assessing congestion, perfusion, BP, renal function and oxygenation.
🔹 3 | Smarter decongestion
IV loop diuretics remain first-line.
If response is inadequate, consider sequential nephron blockade with IV acetazolamide or oral hydrochlorothiazide.
Early urinary sodium assessment may help guide diuretic escalation.
🔹 4 | Treat before discharge
Once stabilized, initiate/optimize foundational therapy—including in-hospital SGLT2 inhibitor initiation.
After discharge, aim for rapid optimization, with uptitration generally every 1–2 weeks when tolerated.
🔹 5 | MRA therapy expands
MRAs now have a broader role across the EF spectrum, including selected patients with HFpEF.
And if EF improves?
➡️ Continue foundational therapy.
🔹 6 | HFpEF becomes increasingly treatable
Beyond SGLT2 inhibitors, treatment now includes broader use of MRAs and selected RAAS inhibition, alongside phenotype-driven management of comorbidities.
🔹 7 | CRT: refined selection and timing
CRT remains Class I A for symptomatic HFrEF with:
➡️ LVEF ≤35%
➡️ sinus rhythm
➡️ LBBB
➡️ QRS ≥150 ms
despite optimal foundational therapy.
In this strong electrical phenotype, CRT planning may begin alongside initiation of foundational therapy, with reassessment before implantation.
⚠️ Evidence remains insufficient to recommend conduction-system pacing as an alternative to CRT in HFrEF.
🔹 8 | ICD: more individualized
Primary prevention:
➡️ Ischaemic HFrEF, LVEF ≤35% → Class I
➡️ Non-ischaemic HFrEF, LVEF ≤35% → Class IIa
Consider competing mortality, comorbidities, frailty, life expectancy and patient preference.
🔹 9 | Obesity becomes a treatment target
In selected symptomatic HF with LVEF ≥45% and BMI ≥30 kg/m², semaglutide or tirzepatide should be considered to improve weight, symptoms, exercise capacity and QoL.
🔹 10 | Precision imaging & aetiology
The focus moves beyond EF toward identifying why the patient has HF, with greater roles for CMR, CT, nuclear imaging and genetic testing.
ATTR-CM therapy also expands to tafamidis, acoramidis and vutrisiran.
🔹 11 | Mitral TEER & haemodynamic monitoring
Mitral TEER receives a Class I recommendation in appropriately selected HFrEF with severe secondary MR despite optimized therapy/CRT.
Pulmonary artery pressure-guided monitoring is strengthened to Class IIa in selected high-risk patients.
📌 The ESC HF 2026 message:
Diagnose earlier → phenotype better → decongest effectively → start treatment early → titrate rapidly → personalize devices and interventions → prevent the next decompensation.
💡 HF management is becoming less about treating an EF number—and more about treating the individual patient’s phenotype, aetiology, haemodynamics and comorbidities.
#ESCCongress #HeartFailure #Cardiology #HFrEF #HFpEF #CRT #SGLT2i #CardiacImaging
CardioCircle retweeted
Proud to share our new publication in Pacing and Clinical Electrophysiology 🫀
17 studies | 3,159 patients | 91% accuracy | 98% specificity
Grateful to an amazing international team!
#Cardiology #Electrophysiology #WPW


































